JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JCM.00803-08v1
46/8/2659    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Lockhart, S. R.
Right arrow Articles by Diekema, D. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lockhart, S. R.
Right arrow Articles by Diekema, D. J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2008, p. 2659-2664, Vol. 46, No. 8
0095-1137/08/$08.00+0     doi:10.1128/JCM.00803-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Geographic Distribution and Antifungal Susceptibility of the Newly Described Species Candida orthopsilosis and Candida metapsilosis in Comparison to the Closely Related Species Candida parapsilosis{triangledown}

Shawn R. Lockhart,1* Shawn A. Messer,1 Michael A. Pfaller,1 and Daniel J. Diekema1,2

Departments of Pathology,1 Internal Medicine, University of Iowa Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa2

Received 28 April 2008/ Returned for modification 5 June 2008/ Accepted 10 June 2008

Candida orthopsilosis and Candida metapsilosis are recently described species, having previously been grouped with the more prevalent species Candida parapsilosis. Current literature contains very little data pertaining to the distributions and antifungal susceptibilities of these Candida species. We determined the species and antifungal susceptibilities of 1,929 invasive clinical isolates from the ARTEMIS antifungal surveillance program collected between 2001 and 2006 and identified as C. parapsilosis using Vitek and conventional methods. Of the 1,929 isolates of presumed C. parapsilosis tested, 117 (6.1%) were identified as C. orthopsilosis and 34 (1.8%) as C. metapsilosis. The percentage of presumed C. parapsilosis isolates found to be C. orthopsilosis varied greatly by region, with the highest percentage (10.9%) from South America and the lowest (0.7%) from Africa. The MIC distributions of the C. orthopsilosis and C. metapsilosis isolates were statistically significantly lower than those of C. parapsilosis for all drugs except fluconazole, for which they were significantly higher (P < 0.001 for all). No C. orthopsilosis or C. metapsilosis isolates were fluconazole resistant, and all were susceptible to caspofungin, anidulafungin, and micafungin.

* Corresponding author. Mailing address: Department of Pathology, University of Iowa Hospitals and Clinics, 6008 BT GH, 200 Hawkins Drive, Iowa City, IA 52242-1009. Phone: (319) 356-2104. Fax: (319) 356-4916. E-mail: shawn-lockhart{at}uiowa.edu

{triangledown} Published ahead of print on 18 June 2008.

Journal of Clinical Microbiology, August 2008, p. 2659-2664, Vol. 46, No. 8
0095-1137/08/$08.00+0     doi:10.1128/JCM.00803-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.